ATE526988T1 - Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren - Google Patents
Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahrenInfo
- Publication number
- ATE526988T1 ATE526988T1 AT04785397T AT04785397T ATE526988T1 AT E526988 T1 ATE526988 T1 AT E526988T1 AT 04785397 T AT04785397 T AT 04785397T AT 04785397 T AT04785397 T AT 04785397T AT E526988 T1 ATE526988 T1 AT E526988T1
- Authority
- AT
- Austria
- Prior art keywords
- methylphenidate
- manufacturing methods
- methylphenidate solution
- solution
- relevant administration
- Prior art date
Links
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001344 methylphenidate Drugs 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000002904 solvent Substances 0.000 abstract 3
- 239000003125 aqueous solvent Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- -1 flavorings Substances 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50970403P | 2003-10-08 | 2003-10-08 | |
| PCT/US2004/033268 WO2005035000A1 (en) | 2003-10-08 | 2004-10-07 | Methylphenidate solution and associated methods of administration and production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE526988T1 true ATE526988T1 (de) | 2011-10-15 |
Family
ID=34435016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04785397T ATE526988T1 (de) | 2003-10-08 | 2004-10-07 | Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7691880B2 (de) |
| EP (1) | EP1680144B1 (de) |
| JP (1) | JP4959335B2 (de) |
| CN (1) | CN1867359B (de) |
| AT (1) | ATE526988T1 (de) |
| AU (1) | AU2004280240B2 (de) |
| CA (1) | CA2540052C (de) |
| ES (1) | ES2373042T3 (de) |
| MX (1) | MXPA06003725A (de) |
| WO (1) | WO2005035000A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2218448B1 (de) | 2002-12-13 | 2015-09-23 | Durect Corporation | Orale Darreichungsform mit flüssigen hochviskose Trägersystemen |
| ATE536867T1 (de) | 2006-03-16 | 2011-12-15 | Tris Pharma Inc | Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen |
| EP2067471B1 (de) | 2007-12-06 | 2018-02-14 | Durect Corporation | Orale arzneimitteldosierformen |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| CN109475505A (zh) | 2016-07-06 | 2019-03-15 | 度瑞公司 | 具有药物组成物、屏障层及药物层的口服剂型 |
| CN106511264A (zh) * | 2016-11-15 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 一种盐酸哌甲酯口服溶液剂及其制备方法 |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| EP4649943A1 (de) * | 2024-05-17 | 2025-11-19 | Medice Arzneimittel Pütter GmbH & Co. KG | Reduzierte nitrosaminbildung in pharmazeutischen zusammensetzungen mit methylphenidat |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| US6486177B2 (en) | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| CN1209098C (zh) * | 1998-06-03 | 2005-07-06 | 阿尔扎有限公司 | 提供药物长效治疗的方法和装置 |
| JP2000072674A (ja) * | 1998-08-28 | 2000-03-07 | Ota Seiyaku Kk | ノスカピン経口医薬液剤 |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| JP2000247883A (ja) * | 1999-02-23 | 2000-09-12 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジン系化合物を含有する内服用液剤 |
| US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
| AU4782600A (en) * | 1999-06-02 | 2000-12-28 | Procter & Gamble Company, The | Oral preparations of etidronate disodium |
| JP2001106629A (ja) * | 1999-10-04 | 2001-04-17 | Material Eng Tech Lab Inc | タンパク分解酵素阻害剤 |
| IL136430A0 (en) * | 2000-05-29 | 2001-06-14 | Zviaguina Natalia | Ray tracing method and system for determining visible parts of surfaces of three-dimensional objects and their parameters of shading accounting for light and shadow volumes |
| DE60027282T2 (de) * | 2000-06-17 | 2007-04-12 | Pharmaquest Ltd., Hamilton | Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression |
| WO2002017919A2 (en) * | 2000-08-28 | 2002-03-07 | Sention, Inc. | Use of threo-methylphenidate compounds to enhance memory |
| US20020132793A1 (en) | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
| TWI277414B (en) * | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| ES2265040T3 (es) * | 2001-05-25 | 2007-02-01 | Warner-Lambert Company Llc | Composicion farmaceutica liquida. |
| AR037131A1 (es) * | 2001-10-31 | 2004-10-20 | Schering Corp | Formulaciones de jarabe de ribavirina |
| US6962908B2 (en) * | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
-
2004
- 2004-10-07 AT AT04785397T patent/ATE526988T1/de not_active IP Right Cessation
- 2004-10-07 CN CN2004800297328A patent/CN1867359B/zh not_active Expired - Lifetime
- 2004-10-07 WO PCT/US2004/033268 patent/WO2005035000A1/en not_active Ceased
- 2004-10-07 US US10/554,133 patent/US7691880B2/en not_active Expired - Lifetime
- 2004-10-07 ES ES04785397T patent/ES2373042T3/es not_active Expired - Lifetime
- 2004-10-07 AU AU2004280240A patent/AU2004280240B2/en not_active Expired
- 2004-10-07 EP EP04785397A patent/EP1680144B1/de not_active Expired - Lifetime
- 2004-10-07 MX MXPA06003725A patent/MXPA06003725A/es active IP Right Grant
- 2004-10-07 JP JP2006534389A patent/JP4959335B2/ja not_active Expired - Lifetime
- 2004-10-07 CA CA2540052A patent/CA2540052C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7691880B2 (en) | 2010-04-06 |
| CN1867359B (zh) | 2010-12-15 |
| JP2007508313A (ja) | 2007-04-05 |
| CN1867359A (zh) | 2006-11-22 |
| ES2373042T3 (es) | 2012-01-30 |
| EP1680144A1 (de) | 2006-07-19 |
| CA2540052A1 (en) | 2005-04-21 |
| MXPA06003725A (es) | 2006-06-23 |
| US20060205776A1 (en) | 2006-09-14 |
| EP1680144B1 (de) | 2011-10-05 |
| WO2005035000A1 (en) | 2005-04-21 |
| JP4959335B2 (ja) | 2012-06-20 |
| AU2004280240A1 (en) | 2005-04-21 |
| AU2004280240B2 (en) | 2010-04-22 |
| CA2540052C (en) | 2012-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0409185A (pt) | formulações veterinárias anti-helmìnticas tópicas | |
| CY1110209T1 (el) | Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα | |
| HK1049165A1 (zh) | 循环β-氨基酸衍生物作为质基金属蛋白酶及TNF-α的抑制剂 | |
| CY1116885T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου | |
| MY146623A (en) | Substituted prolinamides, manufacturing, and the use thereof as medicaments | |
| WO2005009975A3 (en) | Benzimidazole derivatives as mek inhibitors | |
| ATE543873T1 (de) | Herstellung von 3-hydroxypropionsäure mittels beta-alanine-pyruvat-aminotrransferase | |
| EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
| NO20080554L (no) | Pyrazolonderivater | |
| WO2005103037A3 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
| WO2009018065A3 (en) | Novel glucokinase activators and methods of using same | |
| ATE446941T1 (de) | Verfahren zur gekoppelten herstellung von chlor und isocyanaten | |
| WO2006114401A3 (en) | Novel cyclic amines | |
| BR112013028802A2 (pt) | curativo adesivo não aquoso | |
| WO2011076209A3 (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
| TW200517339A (en) | Methods of purifying hydrogen fluoride | |
| WO2009138847A3 (en) | An improved process for the preparation of cefozopran | |
| CY2011018I1 (el) | Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος | |
| WO2008135525A3 (en) | Substituted azetidines, manufacturing and use thereof as medicaments | |
| TW200507867A (en) | Extract of plant dendrobii caulis and preparing process thereof | |
| ATE373029T1 (de) | Monomerenarme, niedrigviskose lösungen von tdi- isocyanuraten in verzweigten dialkylphthalaten | |
| WO2006055532A3 (en) | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof | |
| FR2844273B1 (fr) | Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens. | |
| NO20053089D0 (no) | Carbamidsyreestere med anticolinergisk virkning. | |
| WO2007017585A3 (fr) | Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |